What's in Avidity Biosciences, Inc.'s pipeline?

Avidity Biosciences, Inc. has 5 drugs in our index: 0 marketed, 0 filed, 3 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with Avidity Biosciences, Inc.'s portfolio?

Top competitors by shared drug class: Ionis Pharmaceuticals, Inc., European Organisation for Research and Treatment of Cancer - EORTC, Hoffmann-La Roche, Isarna Therapeutics GmbH, Leadiant Biosciences, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/avidity-biosciences-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Avidity Biosciences, Inc. — Portfolio Competitive Intelligence Brief

Avidity Biosciences, Inc. pipeline: 0 marketed, 0 filed, 3 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
AOC 1001 (del-desiran)	AOC 1001 (del-desiran)	phase 3	Antisense oligonucleotide conjugate		Rare genetic disease
AOC-1020	AOC-1020	phase 3
Del-desiran (AOC 1001)	Del-desiran (AOC 1001)	phase 3	Antisense oligonucleotide	APOC3 mRNA	Cardiovascular

Therapeutic area mix

Cardiovascular · 1
Immunology · 1
Rare genetic disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Ionis Pharmaceuticals, Inc. · 2 shared drug classes
European Organisation for Research and Treatment of Cancer - EORTC · 1 shared drug class
Hoffmann-La Roche · 1 shared drug class
Isarna Therapeutics GmbH · 1 shared drug class
Leadiant Biosciences, Inc. · 1 shared drug class
NYU Langone Health · 1 shared drug class
Pfizer · 1 shared drug class
Sarepta Therapeutics, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Avidity Biosciences, Inc.:

Cite this brief

Drug Landscape (2026). Avidity Biosciences, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/avidity-biosciences-inc. Accessed 2026-05-16.